157 related articles for article (PubMed ID: 17872364)
1. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.
Vellinga MM; Castelijns JA; Barkhof F; Uitdehaag BM; Polman CH
Neurology; 2008 Mar; 70(13 Pt 2):1150-1. PubMed ID: 17872364
[No Abstract] [Full Text] [Related]
2. Is natalizumab overshooting its rebound?
Fox RJ; Kappos L
Neurology; 2008 Mar; 70(13 Pt 2):1073-4. PubMed ID: 18362270
[No Abstract] [Full Text] [Related]
3. Update. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.
Neurology; 2008 Sep; 71(10):780. PubMed ID: 18765659
[No Abstract] [Full Text] [Related]
4. A giant MS plaque mimicking PML during natalizumab treatment.
Twyman C; Berger JR
J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
[TBL] [Abstract][Full Text] [Related]
5. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.
Miravalle A; Jensen R; Kinkel RP
Arch Neurol; 2011 Feb; 68(2):186-91. PubMed ID: 20937940
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of melanoma under concomitant natalizumab therapy.
Vavricka BM; Baumberger P; Russmann S; Kullak-Ublick GA
Mult Scler; 2011 Feb; 17(2):255-6. PubMed ID: 21177318
[No Abstract] [Full Text] [Related]
7. Observations during an elective interruption of natalizumab treatment: a post-marketing study.
Borriello G; Prosperini L; Marinelli F; Fubelli F; Pozzilli C
Mult Scler; 2011 Mar; 17(3):372-5. PubMed ID: 21148264
[TBL] [Abstract][Full Text] [Related]
8. Does natalizumab therapy worsen neuromyelitis optica?
Jacob A; Hutchinson M; Elsone L; Kelly S; Ali R; Saukans I; Tubridy N; Boggild M
Neurology; 2012 Sep; 79(10):1065-6. PubMed ID: 22914835
[No Abstract] [Full Text] [Related]
9. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
[TBL] [Abstract][Full Text] [Related]
10. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
Jander S; Turowski B; Kieseier BC; Hartung HP
Mult Scler; 2012 Nov; 18(11):1650-2. PubMed ID: 23100527
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab dosage suspension: are we helping or hurting?
West TW; Cree BA
Ann Neurol; 2010 Sep; 68(3):395-9. PubMed ID: 20818793
[TBL] [Abstract][Full Text] [Related]
12. Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging.
Chard D; Miller D
J Neurol Sci; 2009 Jul; 282(1-2):5-11. PubMed ID: 19201002
[TBL] [Abstract][Full Text] [Related]
13. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
Vennegoor A; Wattjes MP; van Munster ET; Kriekaart RL; van Oosten BW; Barkhof F; Killestein J; Polman CH
Neurology; 2011 Feb; 76(6):574-6. PubMed ID: 21300973
[No Abstract] [Full Text] [Related]
14. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.
Heesen C; Kleiter I; Nguyen F; Schäffler N; Kasper J; Köpke S; Gaissmaier W
Mult Scler; 2010 Dec; 16(12):1507-12. PubMed ID: 20826527
[TBL] [Abstract][Full Text] [Related]
15. A rare 'palisading' enhancing pattern of multiple sclerosis.
Huang CF; Lo CP; Tseng CY; Chen YC
Eur Neurol; 2012; 67(3):161. PubMed ID: 22261728
[No Abstract] [Full Text] [Related]
16. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
[TBL] [Abstract][Full Text] [Related]
18. Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
Serafini B; Scorsi E; Rosicarelli B; Rigau V; Thouvenot E; Aloisi F
J Neuroimmunol; 2017 Jun; 307():14-17. PubMed ID: 28495131
[TBL] [Abstract][Full Text] [Related]
19. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
20. Significant clinical worsening after natalizumab withdrawal: Predictive factors.
Vidal-Jordana A; Tintoré M; Tur C; Pérez-Miralles F; Auger C; Río J; Nos C; Arrambide G; Comabella M; Galán I; Castilló J; Sastre-Garriga J; Rovira A; Montalban X
Mult Scler; 2015 May; 21(6):780-5. PubMed ID: 25392320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
